Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Steadman Philippon Research Institute
Summary
The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.
Description
This is a double-blind, randomized, placebo-controlled clinical trial proposed to evaluate the efficacy and safety of Losartan for reducing or preventing arthrofibrosis and improving patient-reported outcomes after total knee arthroplasty (TKA). Fibrosis will be evaluated over time after TKA using measures of knee range of motion and capsular thickening. 120 patients scheduled to undergo total knee arthroplasty will be recruited from the clinical practice of the Principal Clinical Investigator or his designee at The Steadman Clinic (TSC) and randomized into one of two arms (1:1).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Planned primary total knee arthroplasty of a single knee; 2. Male or female ≥ 18 years of age; 3. Capacity to personally give informed consent (consent via legally authorized representative will not be accepted) and who are willing to comply with all study-related procedures and assessments. Exclusion Criteria: 1. Breastfeeding, pregnant, or planning to become pregnant during participation in the study; 2. Diagnosed with inflammatory or other arthritis caused by autoimmune disease affecting the study knee; 3. Previous knee arthroplasty on the study knee; 4. Previous i…
Interventions
- DrugLosartan
12.5 mg oral Losartan taken for 28 days total (4 week postoperative).
- DrugPlacebo - Losartan
Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).
Location
- The Steadman ClinicVail, Colorado